Table 3.

Patient response and therapy-associated increases in CK⁺ CTC p16 positivity

	PD	SD	PR
All patients evaluable for clinical response and CTC p16 expression changes (n = 29)
No. pts with increase in proportion of p16-expressing CTCs	5	14	1
No. pts with no increase in proportion of p16-expressing CTCs	5	4	0
Patients with high baseline p16 removed (n = 24)
No. pts with increase in proportion of p16-expressing CTCs	5	14	1
No. pts with no increase in proportion of p16-expressing CTCs	2	2	0

Among the 24 patients with low baseline p16 expression, no significant difference in the rate of PR + SD was observed for patients with an increase in the proportion of p16-expressing CK⁺ CTCs vs. those without (p = 0.55)